Long-Term Outcome of Patients with Postoperative Refractory Diarrhea After Tailored Nerve Plexus Dissection Around the Major Visceral Arteries During Pancreatoduodenectomy for Pancreatic Cancer.
Journal
World journal of surgery
ISSN: 1432-2323
Titre abrégé: World J Surg
Pays: United States
ID NLM: 7704052
Informations de publication
Date de publication:
05 2022
05 2022
Historique:
accepted:
07
01
2022
pubmed:
5
2
2022
medline:
5
4
2022
entrez:
4
2
2022
Statut:
ppublish
Résumé
For pancreatic ductal adenocarcinoma (PDAC) surgery, extended dissection of the nerve plexus (pl) around the superior mesenteric artery (SMA) or celiac artery (CA) is sometimes necessary. This consequently results in postoperative refractory diarrhea. This study aimed to evaluate the clinical impact of extended nerve plexus dissection around major arteries on postoperative diarrhea. Patients who underwent pancreatoduodenectomy (PD) for PDAC between January 2013 and December 2016 were included. The frequency of diarrhea (defined as a condition requiring opioid antidiarrheal drug for at least 6 months after surgery) and its short- and long-term outcomes were reviewed. Of 200 consecutive patients who underwent PD, 78 (39.0%) developed postoperative refractory diarrhea (diarrhea group), and 73 of them (93.6%) underwent hemi-circumferential or more nerve dissection for SMA or CA; both plSMA and plCA dissection were associated with diarrhea. Borderline resectable artery (BR-A) PDAC was included more in the diarrhea group (32.0% vs. 13.1%, P = 0.001); however, the local recurrence rate in the diarrhea group was significantly lower than that in the non-diarrhea group (14.1% vs. 26.2%, P = 0.036). The completion of adjuvant chemotherapy and overall survival were comparable between the two groups. The pre-albumin level improved in 2 years, and 61.3% of patients with diarrhea could stop opioid antidiarrheal drugs within 3 years of surgery. Although the frequency of diarrhea increased following nerve plexus dissection around arteries, diarrhea was controllable and resulted in a reduced local recurrence rate. Aggressive dissection of the nerve plexus may be justified for local disease control in BR-A PDAC.
Sections du résumé
BACKGROUND
For pancreatic ductal adenocarcinoma (PDAC) surgery, extended dissection of the nerve plexus (pl) around the superior mesenteric artery (SMA) or celiac artery (CA) is sometimes necessary. This consequently results in postoperative refractory diarrhea. This study aimed to evaluate the clinical impact of extended nerve plexus dissection around major arteries on postoperative diarrhea.
METHODS
Patients who underwent pancreatoduodenectomy (PD) for PDAC between January 2013 and December 2016 were included. The frequency of diarrhea (defined as a condition requiring opioid antidiarrheal drug for at least 6 months after surgery) and its short- and long-term outcomes were reviewed.
RESULTS
Of 200 consecutive patients who underwent PD, 78 (39.0%) developed postoperative refractory diarrhea (diarrhea group), and 73 of them (93.6%) underwent hemi-circumferential or more nerve dissection for SMA or CA; both plSMA and plCA dissection were associated with diarrhea. Borderline resectable artery (BR-A) PDAC was included more in the diarrhea group (32.0% vs. 13.1%, P = 0.001); however, the local recurrence rate in the diarrhea group was significantly lower than that in the non-diarrhea group (14.1% vs. 26.2%, P = 0.036). The completion of adjuvant chemotherapy and overall survival were comparable between the two groups. The pre-albumin level improved in 2 years, and 61.3% of patients with diarrhea could stop opioid antidiarrheal drugs within 3 years of surgery.
CONCLUSIONS
Although the frequency of diarrhea increased following nerve plexus dissection around arteries, diarrhea was controllable and resulted in a reduced local recurrence rate. Aggressive dissection of the nerve plexus may be justified for local disease control in BR-A PDAC.
Identifiants
pubmed: 35119513
doi: 10.1007/s00268-022-06457-5
pii: 10.1007/s00268-022-06457-5
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1172-1182Informations de copyright
© 2022. The Author(s) under exclusive licence to Société Internationale de Chirurgie.
Références
Pedrazzoli S, DiCarlo V, Dionigi R et al (1998) Standard versus extended lymphadenectomy associated with pancreatoduodenectomy in the surgical treatment of adenocarcinoma of the head of the pancreas: a multicenter, prospective, randomized study lymphadenectomy study group. Ann Surg 228:508–517
doi: 10.1097/00000658-199810000-00007
Yeo CJ, Cameron JL, Sohn TA et al (1999) Pancreaticoduodenectomy with or without extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma: comparison of morbidity and mortality and short-term outcome. Ann Surg 229:613–622
doi: 10.1097/00000658-199905000-00003
Yeo CJ, Cameron JL, Lillemoe KD et al (2002) Pancreaticoduodenectomy with or without distal gastrectomy and extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma, part 2: randomized controlled trial evaluating survival, morbidity, and mortality. Ann Surg 236:355–366
doi: 10.1097/00000658-200209000-00012
Farnell MB, Pearson RK, Sarr MG et al (2005) A prospective randomized trial comparing standard pancreatoduodenectomy with pancreatoduodenectomy with extended lymphadenectomy in resectable pancreatic head adenocarcinoma. Surgery 138:618–628
doi: 10.1016/j.surg.2005.06.044
Nimura Y, Nagino M, Takao S et al (2012) Standard versus extended lymphadenectomy in radical pancreatoduodenectomy for ductal adenocarcinoma of the head of the pancreas: long-term results of a Japanese multicenter randomized controlled trial. J Hepatobiliary Pancreat Sci 19:230–241
doi: 10.1007/s00534-011-0466-6
Jang JY, Kang MJ, Heo JS et al (2014) A prospective randomized controlled study comparing outcomes of standard resection and extended resection, including dissection of the nerve plexus and various lymph nodes, in patients with pancreatic head cancer. Ann Surg 259:656–664
doi: 10.1097/SLA.0000000000000384
Nagakawa T, Kayahara M, Ueno K et al (1992) A clinicopathologic study on neural invasion in cancer of the pancreatic head. Cancer 69:930–935
doi: 10.1002/1097-0142(19920215)69:4<930::AID-CNCR2820690416>3.0.CO;2-R
Nagakawa T, Mori K, Nakano T et al (1993) Perineural invasion of carcinoma of the pancreas and biliary tract. Br J Surg 80:619–621
doi: 10.1002/bjs.1800800526
Nagakawa T, Ueno K, Ohta T et al (1990) Appraisal of extended operation for Carcinoma of the pancreas and biliary tract observated from quality of life. Jpn J Gastroenterol Surg 23:967–972
doi: 10.5833/jjgs.23.967
Orci LA, Meyer J, Combescure C et al (2015) A meta-analysis of extended versus standard lymphadenectomy in patients undergoing pancreatoduodenectomy for pancreatic adenocarcinoma. HPB (Oxford) 17:565–572
doi: 10.1111/hpb.12407
Tol JA, Gouma DJ, Bassi C et al (2014) Definition of a standard lymphadenectomy in surgery for pancreatic ductal adenocarcinoma: a consensus statement by the International Study Group on Pancreatic Surgery (ISGPS). Surgery 156:591–600
doi: 10.1016/j.surg.2014.06.016
Inoue Y, Saiura A, Yoshioka R et al (2015) Pancreatoduodenectomy with systematic mesopancreas dissection using a supracolic anterior artery-first approach. Ann Surg 262:1092–1101
doi: 10.1097/SLA.0000000000001065
Inoue Y, Saiura A, Tanaka M et al (2016) Technical details of an anterior approach to the superior mesenteric artery during pancreaticoduodenectomy. J Gastrointest Surg 20:1769–1777
doi: 10.1007/s11605-016-3214-z
Inoue Y, Saiura A, Oba A et al (2018) Optimal extent of superior mesenteric artery dissection during pancreaticoduodenectomy for pancreatic cancer: balancing surgical and oncological safety. J Gastrointest Surg 16:1373–1383
Inoue Y, Saiura A, Takahashi Y (2018) A novel classification and staged approach for dissection along the celiac and hepatic artery during pancreaticoduodenectomy. World J Surg 42:2963–2967. https://doi.org/10.1007/s00268-018-4550-9
doi: 10.1007/s00268-018-4550-9
pubmed: 29464344
Sobin L, Gospodarowicz M, Wittekind C (2009) Pancreas. In: TNM classification of malignant tumours, 7th edn. Wiley-Blackwell, 2010, Chichester, West Sussex, UK ; Hoboken, NJ, England, p 132–135
Tempero MA, Malafa MP, Al-Hawary M et al (2017) Pancreatic adenocarcinoma, version 2.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 15:1028–1061
doi: 10.6004/jnccn.2017.0131
Tanaka M, Inoue Y, Matsueda K et al (2020) Three-dimensional fixation: pathological protocol following pancreaticoduodenectomy with portal vein resection for pancreatic cancer. J Gastrointest Surg 24:619–626
doi: 10.1007/s11605-019-04203-2
Clavien PA, Barkun J, de Oliveira ML et al (2009) The Clavien-Dindo classification of surgical complications: 5-year experience. Ann Surg 250:187–196
doi: 10.1097/SLA.0b013e3181b13ca2
Dindo D, Demartines N, Clavien PA (2004) Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 240:205–213
doi: 10.1097/01.sla.0000133083.54934.ae
Uesaka K, Boku N, Fukutomi A et al (2016) Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01). Lancet 388:248–257
doi: 10.1016/S0140-6736(16)30583-9
Thorsen Y, Stimec BV, Lindstrom JC et al (2021) Stool dynamics after extrinsic nerve injury during right colectomy with extended D3-mesenterectomy. Scand J Gastroenterol 56:770–776
doi: 10.1080/00365521.2021.1918757
Thorsen Y, Stimec BV, Lindstrom JC et al (2019) Bowel motility after injury to the superior mesenteric plexus during D3 extended mesenterectomy. J Surg Res 239:115–124
doi: 10.1016/j.jss.2019.02.004
Thorsen Y, Stimec B, Andersen SN et al (2016) Bowel function and quality of life after superior mesenteric nerve plexus transection in right colectomy with D3 extended mesenterectomy. Tech Coloproctol 20:445–453
doi: 10.1007/s10151-016-1466-y
Varadhachary GR, Tamm EP, Abbruzzese JL et al (2006) Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy. Ann Surg Oncol 13:1035–1046
doi: 10.1245/ASO.2006.08.011
Vauthey JN, Dixon E (2009) AHPBA/SSO/SSAT consensus conference on resectable and borderline resectable pancreatic cancer: rationale and overview of the conference. Ann Surg Oncol 16:1725–1726
doi: 10.1245/s10434-009-0409-5
Tempero MA, Arnoletti JP, Behrman SW et al (2012) Pancreatic Adenocarcinoma, version 2.2012: featured updates to the NCCN Guidelines. J Natl Compr Canc Netw 10:703–713
doi: 10.6004/jnccn.2012.0073
Katz MH, Marsh R, Herman JM et al (2013) Borderline resectable pancreatic cancer: need for standardization and methods for optimal clinical trial design. Ann Surg Oncol 20:2787–2795
doi: 10.1245/s10434-013-2886-9
Nagakawa T, Kayahara M, Ueno K et al (1992) Clinicopathological study on neural invasion to the extrapancreatic nerve plexus in pancreatic cancer. Hepatogastroenterology 39:51–55
pubmed: 1314766
Maeda A, Boku N, Fukutomi A et al (2008) Randomized phase III trial of adjuvant chemotherapy with gemcitabine versus S-1 in patients with resected pancreatic cancer: Japan adjuvant study group of pancreatic cancer (JASPAC-01). Jpn J Clin Oncol 38:227–229
doi: 10.1093/jjco/hym178
Motoi F, Kosuge T, Ueno H et al (2019) Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02/JSAP05). Jpn J Clin Oncol 49:190–194
doi: 10.1093/jjco/hyy190
Motoi F, Satoi S, Honda G et al (2019) A single-arm, phase II trial of neoadjuvant gemcitabine and S1 in patients with resectable and borderline resectable pancreatic adenocarcinoma: PREP-01 study. J Gastroenterol 54:194–203
doi: 10.1007/s00535-018-1506-7
Takahashi H, Ohigashi H, Gotoh K et al (2013) Preoperative gemcitabine-based chemoradiation therapy for resectable and borderline resectable pancreatic cancer. Ann Surg 258:1040–1050
doi: 10.1097/SLA.0b013e31829b3ce4
Talamonti MS, Small W Jr, Mulcahy MF et al (2006) A multi-institutional phase II trial of preoperative full-dose gemcitabine and concurrent radiation for patients with potentially resectable pancreatic carcinoma. Ann Surg Oncol 13:150–158
doi: 10.1245/ASO.2006.03.039
Okano K, Suto H, Oshima M et al (2017) A prospective phase II trial of neoadjuvant S-1 with concurrent hypofractionated radiotherapy in patients with resectable and borderline resectable pancreatic ductal adenocarcinoma. Ann Surg Oncol 24:2777–2784
doi: 10.1245/s10434-017-5921-4
Eguchi H, Takeda Y, Takahashi H et al (2019) A prospective, open-label, multicenter phase 2 trial of neoadjuvant therapy using full-dose gemcitabine and S-1 concurrent with radiation for resectable pancreatic ductal adenocarcinoma. Ann Surg Oncol 26:4498–4505
doi: 10.1245/s10434-019-07735-8
Hackert T, Strobel O, Michalski CW et al (2017) The TRIANGLE operation–radical surgery after neoadjuvant treatment for advanced pancreatic cancer: a single arm observational study. HPB (Oxford) 19:1001–1007
doi: 10.1016/j.hpb.2017.07.007
Diener MK, Mihaljevic AL, Strobel O et al (2020) Periarterial divestment in pancreatic cancer surgery. Surgery 169(5):1019–1025
doi: 10.1016/j.surg.2020.08.030